Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCUR-101 + ADT in mCRPC
NCT03137758Phase 1Terminated
- Sponsor
- Pellficure Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of plumbagin in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Pellficure Pharmaceuticals. Primary endpoint: Toxicities and Adverse Events at 28 days. Started Jul 2017; status: terminated.
02
Drugs
plumbagin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03137758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137758.